A research team at the Brain Research Institute, Niigata University has found that APOE ε4, a genetic factor best known for increasing the risk of Alzheimer's disease, may also influence how ...

A new study, published in Cell Reports, reports a novel mechanism behind dysregulated neuronal activity, a key pathology of amyotrophic lateral sclerosis (ALS). Researchers at King's College London ...

A protein long studied for its role in amyotrophic lateral sclerosis and frontotemporal dementia now appears to serve a second, equally critical function, safeguarding the integrity of human DNA.

Patients with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, live an average of only three years after symptoms begin, though some can survive closer to 10 years. What drives these ...

A new study from scientists at Northwestern University Feinberg School of Medicine sheds light on how amyotrophic lateral sclerosis (ALS) unfolds in the body. Specifically, they found that the disease ...

Researchers from Macquarie University have detailed the discovery of a novel gene therapy vector targeting pathological TAR-binding protein 43 (TDP-43), CTx-1000, as a potential therapeutic candidate ...

Shu Chen, Ph.D., Professor, Neuropathology, was awarded a strategic initiative grant from the Amyotrophic Lateral Sclerosis (ALS) Association, for his project, "Development of Skin Biomarker for Early ...

APOE ε4 was found to be directly associated with the pathological classification of TDP-43 in ALS, whereas Alzheimer’s disease–related proteins, including amyloid-β and tau, showed no significant ...

Study used cutting-edge techniques to analyze blood, spinal cord samples from hundreds of patients Immune signatures differ by ALS type (genetic or non-genetic), disease stage, speed of progression ...